All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population

Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance

(2013) E. Ahlqvist et al.   DIABETES

Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide Study

(2013) Anne-Marie Schjerning Olsen et al.   PLoS One

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

(2013) D. T. Eurich et al.   BMJ-British Medical Journal

Cardiovascular effects of the DPP-4 inhibitors

(2012) Tessey Jose et al.   Diabetes & Vascular Disease Research

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

(2012) B. Hemmingsen et al.   BMJ-British Medical Journal

Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials

(2012) Rémy Boussageon et al.   PLOS MEDICINE

Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?

(2011) Bo Ahrén   Current Diabetes Reports

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

(2011) Tina Ken Schramm et al.   EUROPEAN HEART JOURNAL

Metformin Use and Mortality Among Patients With Diabetes and AtherothrombosisMetformin Use With Diabetes and Atherothrombosis

(2010) Ronan Roussel   ARCHIVES OF INTERNAL MEDICINE

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1 

(2010) G. P. Fadini et al.   DIABETES CARE

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

(2010) C. Lamanna et al.   DIABETES OBESITY & METABOLISM

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial

(2009) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

(2009) P. Aschner et al.   DIABETES OBESITY & METABOLISM

Cardiovascular Outcomes in Trials of Oral Diabetes Medications

(2008) Elizabeth Selvin et al.   ARCHIVES OF INTERNAL MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE